News
Lilly, Novo Nordisk and Zepbound
Digest more
Hosted on MSN3d
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders WaryEli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results